至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

An additional site mutation in STING/MITA gain-of-function mutants abolishes the autoimmune SAVI phenotypes and directs a therapeutic strategy

Cell Insight. 2026-06; 
Fang-Xu Li, Sheng Liu, Zhi-Dong Zhang, Xin Shuai, Bi-Kun Xiao, Jia Yang, Defen Lu, Dandan Lin, Guijun Shang, Bo Zhong
Products/Services Used Details Operation
Peptide Synthesis TAT-SIP1/2, TAT-WT/NS and TAT were synthesized by GenScript Inc. with over 95% purity. Get A Quote

摘要

STING-associated vasculopathy with onset in infancy (SAVI) is an autoimmune disease caused by gain-of-function mutations (GOFs) of MITA/STING and the most frequent GOFs for SAVI are MITAN154S and MITAV155M. However, how MITA GOFs are spontaneously activated remains incompletely understood. Here, we show that the activity of MITA hinge-region GOFs is compromised by an additional mutation at Lys150 and that the SAVI phenotypes of MITAN153S/WT mice are completely abolished in the MITAK150N/N153S (MITANS/NS) mice. Mechanistically, MITA GOFs constitutively associate with iRhom2 for the spontaneous ER-to-Golgi translocation, which is substantially inhibited by the introduction of a mutation at Lys150. Interestingly, ... More

关键词

ER-To-Golgi translocation; MITA gain-of-function mutations; MITA/STING; SAVI; SAVI-Inhibitory peptide; Therapeutic intervention.